Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)

Alzheimer Disease Clinical Trial

— ISDC  

Official title:

Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02819700
• Other study ID #: PI11-PR-GODEFROY-2
• Status: Completed
• Start date: January 29, 2013
• Est. completion date: January 28, 2018

Study information

• Verified date: July 2020
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic importance, as they often constitute the initial symptoms of Frontotemporal Dementia (FTD), Semantic Dementia (SD) and Huntington's disease (HD) and they are classically more frequent in vascular dementia (VaD) than in Alzheimer's disease (AD). The presence of these disorders at the stage of Mild Cognitive Impairment (MCI) has only been partially evaluated and would increase the risk of progression to dementia. These classical data are based on non-standardized assessments and non-validated diagnostic criteria. The Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX) has developed a standardized assessment tool for behavioural dysexecutive disorders, the Behavioural Dysexecutive Syndrome Inventory (BDSI) and has validated diagnostic criteria for this syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: January 28, 2018
• Est. primary completion date: January 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Support to the consultation memory for a neurological disease ( frontotemporal dementia , vascular dementia , Alzheimer's disease , mild cognitive disorder, Huntington's disease ( with genetic diagnosis confirmed : number of CAG triplets > 36 symptomatic : UHDRS score =5 ) with MMS > 15

• Age 40 to 85 years

• French

• Informing reliable

• Agreeing to participate in the study.

Exclusion Criteria:

• Presence of other disease disturbing behavior ( current depressive syndrome , schizophrenia, psychosis , past psychiatric disorders requiring a stay > 2 days in a specialized environment ) or cognition (mental retardation , illiteracy , respiratory failure, kidney , liver , heart ) or preventing the realization of the tests ( perceptual or motor deficit ) intrecérébrale pacing therapy or stem cell transplant , patient protected ( under supervision or guardianship ) , pregnant and / or breastfeeding and lack of consent

Related Conditions & MeSH terms

• Alzheimer Disease
• Aphasia, Primary Progressive
• Dementia
• Dementia, Vascular
• Frontotemporal Dementia
• Huntington Disease
• Pick Disease of the Brain
• Semantic Dementia

Intervention

Behavioral:
• prevalence of behavioural dysexecutive syndrome
Behavioural Dysexecutive Syndrome Inventory (ISDC)

Locations

Country	Name	City	State
France	CHU Amiens	Amiens
France	CHU Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ISDC (Behavioural Dysexecutive Syndrome Inventory)	Behavioural Dysexecutive Syndrome Inventory	Day 0